Skip to content
lifestyle.entreprenerd.net
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Tech
Travel
Author:
Eupraxia Pharmaceuticals Inc.
Eupraxia Pharmaceuticals Establishes At-The-Market Offering Program
November 10, 2026
Eupraxia Pharmaceuticals Reports Third Quarter 2026 Financial Results
November 10, 2026
Eupraxia Pharmaceuticals to Participate at Upcoming Conferences and Host a Virtual Analyst Day
October 22, 2026
Eupraxia Pharmaceuticals Reaches its Enrollment Target for the RESOLVE Trial Investigating EP-104GI for the Treatment of Eosinophilic Esophagitis
October 15, 2026
Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences
October 9, 2026
Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis
September 30, 2026
Eupraxia Pharmaceuticals Joins Nasdaq Global Select Market
September 8, 2026
Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients
August 13, 2026
Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results
August 11, 2026
Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of Growth
July 13, 2026
1
2
Next Page
→